Stopped: Zimmer Biomet no longer intends to market the M/L Taper with Kinectiv in the European Union and therefore has terminated study MDRG2017-89MS-56H.
The objective of this consecutive series PMCF study is to collect data confirming safety, performance and clinical benefits of the M/L Taper with Kinectiv Technology Stems and Necks when used for primary or revision total hip arthroplasty (implants) at 1,2,5 and 10-year follow-up\*. ML Taper with Kinectiv Technology has been on the market since 2008, but has insufficient long term clinical data. Therefore, a prospective aspect to the study will be necessary to reach the 10-year time point.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Device safety assessed through the frequency and incidence of revisions, complications and adverse events
Timeframe: Out to 10 Years.
Device safety assessed through radiographic assessments
Timeframe: Out to 10 Years